Sanofi Bags Genzyme With Incentive-Laden $20B Offer

Law360, New York (February 16, 2011, 12:31 PM EST) -- French pharmaceutical giant Sanofi-Aventis SA reached a $20.1 billion deal to buy Genzyme Corp. Wednesday, bumping its offer to $74 per share and tacking on incentives for Genzyme investors that could reach $14 per share in additional cash.

In addition to the cash payment, each Genzyme shareholder will receive rights to additional payments if specified milestones related to Genzyme's multiple sclerosis drug alemtuzumab, sold under the name Lemtrada, are reached.

Genzyme CEO Henri Termeer said in August that alemtuzumab has "tremendous future upside" and demanded that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.